The btg1 (B-cell translocation gene 1) gene coding sequence was isolated from a translocation break point in a case of B-cell chronic lymphocytic leukaemia. We have already shown that BTG1, considered as an antiproliferative protein, strongly stimulates myoblast differentiation. However, the mechanisms involved in this influence remained unknown. In cultured myoblasts, we found that BTG1 stimulates the transcriptional activity of nuclear receptors (T3 and all-trans retinoic acid receptors but not RXRa and PPARc), c-Jun and myogenic factors (CMD1, Myf5, myogenin). Immunoprecipitation experiments performed in cells or using in vitro-synthesized proteins and GST pull-down assays established that BTG1 directly interacts with T3 and all-trans retinoic acid receptors and with avian MyoD (CMD1). These interactions are mediated by the transactivation domain of each transcription factor and the A box and C-terminal part of BTG1. NCoR presence induces the ligand dependency of the interaction with nuclear receptors. Lastly, deletion of BTG1 interacting domains abrogates its ability to stimulate nuclear receptors and CMD1 activity, and its myogenic influence. In conclusion, BTG1 is a novel important coactivator involved in the regulation of myoblast differentiation. It not only stimulates the activity of myogenic factors, but also of nuclear receptors already known as positive myogenic regulators.
Introduction
The btg1 (B-cell translocation gene 1) gene coding sequence was isolated from a translocation break point in a case of B-cell chronic lymphocytic leukaemia (Rouault et al., 1992) . Highly conserved in all animal species, it belongs to a gene family encoding proteins characterized by the occurrence of two well-conserved A and B boxes. BTG1 is ubiquitously expressed in adult animals (Bradbury et al., 1991; Rouault et al., 1992 ). However, its expression level is particularly important in quiescent tissues such as liver or thymus, where cell proliferation could be reactivated by several stimuli. By contrast, it is lower in differentiated tissues such as muscle or nerve adult tissues (Rouault et al., 1992) . Initially, Rouault et al. (1992) demonstrated the strong antiproliferative activity of BTG1, more recently established for other members of the BTG family, such as BTG2 (Rouault et al., 1996) , Tob (Matsuda et al., 1996) and BTG3 (Yoshida et al., 1998) .
In further studies, we observed that BTG1 expression is induced at the onset of myoblast differentiation when irreversible withdrawal from the cell cycle occurs . We have established that, at this stage, stimulation of RXR expression allows the triiodothyronine (T3) nuclear receptor c-ErbAa1 (TRa1) to inhibit AP-1 activity (Cassar-Malek et al., 1996) , known as a potent repressor of myoblast differentiation. Interestingly, as elevated AP-1 (Jun/ Fos) activity represses BTG1 expression , this pathway also contributes to the induction of BTG1 expression.
Furthermore, BTG1 overexpression mimics the positive myogenic influence of T3 by inducing myoblast withdrawal from the cell cycle and stimulating terminal differentiation . We also reported that BTG1 is submitted to cellular trafficking and that T3 increases the nuclear localization of the protein. Interestingly, whereas a BTG1 mutant located in the cytoplasm is devoid of any myogenic activity, a mutant displaying major nuclear localization increases myoblast withdrawal from the cell cycle and stimulates myoblast differentiation (Rodier et al., 2001) . These data established that BTG1 exerts its myogenic influence at nuclear level, and is a T3 target involved in the control of myoblast differentiation by the hormone .
To date, the molecular basis of BTG1 influence is poorly understood. Some studies have initially reported BTG mechanisms induced at cytoplasmic level by interaction of Tob with the membrane receptor Erb B2 (Matsuda et al., 1996) . However, further reports clearly suggest that BTG proteins could also interact with proteins involved in transcriptional regulation. First, Lin et al. (1996) reported the occurrence of a physical interaction between BTG1 and PRMT1 (protein arginine N-methyl-transferase), a protein methylating arginine residues occurring in hnRNP or histones, thus controlling transcription through histone methylation. Likewise, BTG1 has been shown to interact with carbon catabolite repressor protein-associated factor 1 (CAF-1), a component of the CCR4 transcriptional complex (Rouault et al., 1998) . More recently, Prevot et al. (2000) demonstrated that BTG1 and BTG2 act as transcriptional cofactors of the homeo box B9 protein (Hoxb9). In addition, both BTG1 and BTG2 significantly enhanced the ERa activity (Prevot et al., 2001) . Lastly, the occurrence of two LxxLL motifs in the protein sequence required for interaction of a number of coactivators with nuclear receptors (Heery et al., 1997) suggests that BTG1 could also act as a nuclear receptor coactivator.
To test this possibility, we studied the direct interaction of BTG1 with several nuclear receptors involved in the regulation of myoblast differentiation, such as TRa1 (Cassar-Malek et al., 1994) or RAR (Albagli-Curiel et al., 1993) , and its influence on their transcriptional activity. Taking into account the potent myogenic influence of BTG1, a similar study was performed with regard to myogenic factors. This study led us to conclude that BTG1 is a common coactivator for nuclear receptors and myogenic factors, which satisfactorily explains its myogenic influence.
Results

BTG1 enhances the transcriptional activity of nuclear receptors
In QM7 myoblasts, the influence of BTG1 on the wildtype (WT) T3 receptor TRa1 was assessed in transient transfection experiments using a DR4-tk-CAT (CAT: chloramphenicol acetyltransferase) reporter gene. In agreement with previous data (Cassar-Malek et al., 1996) , TRa1 did not by itself significantly stimulate reporter gene activity in proliferating myoblasts, but RXRg coexpression induced its transcriptional activity in the presence of T3 (3.1 times more than basal gene reporter activity, Po0.01; Figure 1a ). Cotransfection of BTG1 induced significant activity of liganded TRa1 (Po0.01) and moderately but significantly increased the transcriptional influence recorded after coexpression of TRa1 and RXRg (Po0.05), in the presence of T3 (Figure 1a) .
To study the functional TRa1/BTG1 interaction without any interference by RXR expression, we performed similar experiments using the Gal4 system (gal4-tk-CAT reporter and a chimeric T3 receptor including the DNA-binding domain of GAL4 fused to the hinge region and the ligand-binding domain of TRa1). In these conditions, homodimers of the chimeric T3 receptor stimulate transcription of the reporter gene. In the presence of T3, Gal4-TRa1 expression induced a 35.9-fold stimulation of the basal promoter activity (Po0.001; Figure 1b ). Although devoid of any significant influence by itself, BTG1 coexpression significantly increased the Gal4-TRa1 transcriptional influence (Po0.001) in the presence of ligand. This result, in agreement with that obtained with the WT receptor, additionally established that the specific NH 2 -terminus and DNA-binding domain of TRa1 are not involved in this interaction.
We also assessed the ability of BTG1 to increase the activity of other members of the nuclear receptor superfamily. We found that BTG1 coexpression significantly potentiated stimulation of a gal4-tk-CAT reporter gene by a chimeric Gal4-RARa receptor in the presence of all-trans retinoic acid (RA; Figure 1c , Po0.001). However, we did not observe a significant influence on RXRa activity in the presence of 9-cis retinoic acid (10 nM; Figure 1d ) or on PPARg/RXRg activity in the presence of clofibrate (100 mM; Figure 1e ), thus indicating that the transcriptional influence of BTG1 is restricted to particular nuclear receptors.
BTG1 enhances the activity of transcription factors involved in the regulation of muscle development
The influence of BTG1 on CMD1 (avian MyoD) transcriptional activity was studied using a CAT reporter gene driven by a minimal myogenin promoter including two E boxes. CMD1 induces an 11.6-fold stimulation of myogenin promoter basal activity (Figure 2a , Po0.001), an influence potentiated by BTG1 coexpression (Po0.005).
BTG1 increased also the activity of myogenin and Myf5 (Figure 2b and c, Po0.001 and Po0.005, respectively). Similar results were obtained using another promoter regulated by MyoD (b-tropomyosin promoter, data not shown).
C-Jun is considered both as a negative and positive regulator of myoblast differentiation according to the nature of its dominant partner . Therefore, we studied the influence of BTG1 on its transcriptional activity (Figure 2d ). We found that BTG1 coexpression also increased stimulation by cJun of a À73Col-CAT reporter gene activity (Po0.05).
BTG1 physically interacts with nuclear receptors
We tested BTG1 physical interaction with nuclear receptors (TRa1, TRb1, RARa, RXRa, PPARg), myogenic factors (CMD1 and myogenin) and c-Jun. After transient transfection of vectors expressing TRa1 and/or a BTG1-flag protein in QM7 myoblasts, coimmunoprecipitation experiments were performed on cell lysates using specific antibodies raised against the TR or the flag sequence. We found that the flag antibody immunoprecipitates TRa1 only when BTG1-flag was coexpressed (Figure 3a) . In a second approach, we have assessed the physiological relevance of this interaction with the endogenous T3 receptor. As no antibody able to immunoprecipitate physiological amounts of BTG1 or detect BTG1 by Western blotting BTG1: a myogenic coactivator M Busson et al is presently available, we have transfected 1 or 0.1 mg/ dish of a vector encoding the BTG1-flag protein in QM7 myoblasts. We found that the endogenous c-ErbAa1 receptor was co-immunoprecipitated by the flag antibody even with using a very small amount of BTG1-flag vector, thus indicating that, indeed, the receptor and BTG1 are present in a common protein complex (Figure 3b ).
In GST pull-down experiments, we obtained additional indications that TRa1 directly interacts with BTG1 ( Figure 3c ). This experimental procedure was validated in co-immunoprecipitation assays using in vitro-synthesized [ (Figure 3d , lane 1). All these data led us to conclude that BTG1 does indeed physically interact with TRa1. In parallel, we also provided evidence by GST pull-down experiments that TRb and RARa interact with BTG1 (Figure 3e and f). In addition, we found that these in vitro TRa1 and RARa interactions are independent of the presence of T3 or RA. In agreement with our functional studies, we failed to detect any significant interaction of BTG1 with RXRa and PPARg in the presence (Figure 3g ) or absence (data not shown) of their respective ligands. In these in vitro systems, the influence of nuclear corepressors is not considered. Interestingly, addition of cell extracts overexpressing NCoR (Figure 3h ) induced a ligand dependence in BTG1/TRa1 or BTG1/RAR interaction ( Figure 3i ). Whereas no interaction was detected between the unliganded T3 receptor or RAR and BTG1 in the presence of NCoR, addition of 1 nM T3 or 100 nM RA restored the ability of GST-BTG1 to retain TRa1 or RAR.
Further experiments were performed to characterize the TRa1 domains involved in the interaction with BTG1. For this purpose, we used different in vitrosynthesized deletion mutants of the receptor in GST pull-down experiments. In agreement with the functional assays previously described, the amino-terminal region and the DNA-binding domain of TRa1 were not required to interact with BTG1. Deletion of the AF2 carboxy-terminal region of the receptor decreased interaction intensity by 40% (Figure 4b , mutant TR(1-400)), whereas a mutant deleted of the full-length ligand-binding domain did not significantly interact (mutant TR(1-194)), thus indicating (i) a major role for the AF2 domain involved in the nuclear receptor transcriptional activity and (ii) complementary involvement of the full-length TRa1 ligand-binding domain.
Searches for BTG1 sequences involved in the interaction with TRa1 led to the conclusion that mutations of LxxLL sequences considered as driving interaction of several nuclear coactivators with nuclear receptors did not significantly impair the ability of GST-BTG1 to retain TRa1 (Figure 5c , lanes b1, b2, b3 vs a). Instead of that, BTG1 A box was involved in the interaction ( Figure 5c , lanes c, d, e, f and k). Furthermore, we also established the occurrence of a second region driving interaction located in the carboxy-terminus part of BTG1 ( Figure 5c , lanes h and i).
BTG1 physically interacts with transcription factors involved in the regulation of myoblast differentiation (CMD1 and c-Jun)
After transient overexpression of CMD1 and/or BTG1-flag in QM7 myoblasts, we observed that the flag antibody immunoprecipitates CMD1 only after BTG1-flag coexpression (Figure 6a ), thus indicating that CMD1 and BTG1 are present in a common protein complex. GST pull-down assays and/or co-immunoprecipitation experiments using in vitro-synthesized proteins established that BTG1 directly interacts with CMD1 ( Figure 6b and c), and extended this result to c-Jun (Figure 6d ). In addition, we also performed coimmunoprecipitation experiments in order to assess the BTG1/myogenin physical interactions. BTG1-flag and/ or myogenin were expressed in proliferative myoblasts, and therefore in the absence of endogenous myogenin. In these conditions, the flag antibody immunoprecipitated the myogenic factor only when BTG1-flag was coexpressed with myogenin ( Figure 6e ). As previously performed to assess interactions with the T3 receptor, 1 or 0.1 mg of the BTG1-flag expression vector was transfected in QM7 myoblasts, and interactions were studied at the onset of myoblast differentiation, when endogenous myogenin is already expressed. We found that the endogenous myogenic factor was co-immunoprecipitated by the flag antibody even when using a very small amount of the BTG1-flag vector, thus indicating that, indeed, myogenin and BTG1 are present in a common protein complex (Figure 6f) .
Further experiments addressed the identification of the CMD1 domains involved in interaction with BTG1. In GST pull-down experiments, we found that the NH 2 -terminus of CMD1 can mediate the interaction with [ Interestingly, the NH 2 -terminal domain of CMD1 is considered to be the sequence involved in the transcriptional activity of the myogenic factor (Weintraub et al., 1991) . We also searched for the BTG1 sequences involved in interaction with CMD1 ( Figure 8 ). As 1-73, 1-98, 1-117 and 52-98 BTG1 mutants interacted with CMD1, unlike 1-52 and 73-117 mutants, we concluded that, as for TRa1, BTG1 A box is involved in the interaction with the myogenic factor ( Figure 8, lanes d, e, f and k) . Moreover, study of the 98-171, 117-171 and 129-171 mutants led to the conclusion that the BTG1 C box is a second domain of interaction with CMD1 ( Figure 8 , lanes g, h and I, respectively).
Deletion of the A box and carboxy-terminus part of BTG1 abrogates both its coactivator activity and its myogenic influence
To assess the functional importance of the BTG1 domains involved in the physical interaction with CMD1 and TRa1, we performed transient transfection experiments with several BTG1 mutants harbouring deletion of the A box (mutant DA: D52-73), the TRα1 GFP TRα1 GFP carboxy-terminus (f mutant: BTG1 1-117) or both regions. We also tested the influence of leucine substitutions by alanine in the first, second or both BTG1 LxxLL motifs.
In agreement with our previous observations indicating that these sequences are not involved in physical interactions between TRa1, CMD1 and BTG1, mutations of LxxLL sequences did not impair the ability of BTG1 to stimulate Gal4-TRa1 or CMD1 activity (data not shown). By contrast, deletion of the A box or the carboxy-terminus of BTG1 moderately reduced BTG1 influence on TRa1 transcriptional activity (Po0.05 and Po0.05, respectively). Furthermore, the influence of BTG1 on TRa1 transcriptional activity was fully abrogated by deletion of the two domains (Figure 9a ). Similar results were obtained for the influence of BTG1 mutants on CMD1 transcriptional activity (BTG1 DA, BTG1 1-117 and BTG1 1-117 DA compared to WT BTG1: Po0.05, Po0.05 and Po0.01; Figure 9b ).
In parallel, we assessed the myogenic activity of each BTG1 mutant and studied the influence of a BTG1 mRNA antisens. In good correlation with the previous functional data, deletions of the interacting domains decreased its myogenic activity. Deletion of the A box or the C-terminal part of the protein resulted in the formation of a reduced number of thinner myotubes than was observed after expression of WT BTG1, well reflected by a lower fusion index value (16.3 and 17.0% vs 25.1%, respectively, Po0.05; Figure 9d ) and reduced accumulation of connectin ( Figure 9c ) and myosin ( Figure 9e ) 2 days after the onset of terminal differentiation. In addition, deletion of the two interacting domains previously identified in BTG1 led to a more drastic reduction of myogenic activity (fusion index: 11.2%, Po0.05 compared to WT BTG1). Lastly, in agreement with the positive influence of BTG1 on 
Neither trichostatin nor PRMT1 overexpression influences BTG1 coactivator activity
In order to obtain some insights concerning the molecular basis of BTG1 coactivator activity, we have tested the possibility that it could recruit a complex including histone acetyltransferase (HAT) proteins. For this purpose, we used trichostatin, a well-known inhibitor of histone deacetylation. As expected, this drug induced a 1.5-fold stimulation of liganded Gal4-TRa1 transcriptional activity, as previously described for several nuclear receptors (Yoshida et al., 1995) . However, it did not significantly affect the ability of BTG1 to stimulate T3 receptor activity (Figure 10a ).
PRMT1, a protein arginine N-methyl-transferase, is considered as a coactivator of nuclear receptors (Koh et al., 2001) able to interact with BTG1 . As expected, PRMT1 coexpression stimulated Gal4-TRa1 transcriptional activity ( Â 2.1, Po0.005), but was without any influence in the presence of BTG1 (Figure  10b ), in agreement with the observation that, in GST pull-down experiments, the direct interaction between GST-BTG1 and PRMT1 was fully abrogated in the presence of the T3 receptor c-ErbAa1 (data not shown). Interestingly, we also found that PRMT1 coexpression induces a significant stimulation of CMD1 transcriptional activity ( Â 2.2, Po0.01). However, as reported for TR a1, it did not affect BTG1 coactivator activity relatively to CMD1 (Figure 10c ).
This set of data led to the conclusion that BTG1 coactivator activity does not involve interactions with HAT or with PRMT1.
Discussion
We have previously established that BTG1 stimulates myoblast withdrawal from the cell cycle and increases the extent of terminal differentiation . In addition, we provided evidence that BTG1, submitted to cell trafficking, exerts its myogenic activity at nuclear level (Rodier et al., 2001) . These data led us to As the protein displayed two LxxLL motifs considered to be involved in the interaction of coactivators with nuclear receptors (Heery et al., 1997) , we privileged the possibility that BTG1 could act as a coactivator of several transcription factors.
BTG1 is a coactivator of positive regulators of myoblast differentiation
Some nuclear receptors are clearly involved in the regulation of myoblast differentiation, such as RA (Albagli-Curiel et al., 1993) , T3 or 9-cis RA receptors (Cassar-Malek et al., 1994 . More recently, a cJun-positive myogenic influence has been reported, in conjunction with its ATF2 partner . In this study, we found that BTG1 displays two important features required for classification as a nuclear coactivator: (i) stimulation of the transcriptional activity of transcription factors and (ii) direct physical interaction with these transcription factors.
We have provided evidence that BTG1 stimulates TRa1 and RARa transcriptional activity to a similar extent as reported for other coactivators (Monden et al., 1997; Treuter et al., 1998; Ko et al., 2000) and physically interacts with these receptors. As previously shown for PGC1a (Puigserver et al., 1998) , we first observed that this interaction occurred in the absence and presence of the respective ligands of each receptor, leading us to study the possibility that, in the absence of ligands, binding of a corepressor molecule to nuclear receptors could impair their ability to interact with BTG1. Addition of NCoR-enriched cell extracts to the in vitro assay fully abrogated BTG1 binding to TRa1 and RARa in the absence of ligands. Furthermore, addition of T3 or RA restored the binding, probably by inducing dissociation of NCoR from the receptors (Horlein et al., 1995) ; these observations clearly suggest that BTG1 and NCoR interactions cannot occur simultaneously. In addition, in parallel to the lack of BTG1 influence on RXRa and PPARg transcriptional activity, we failed to detect any physical interaction of the antiproliferative protein with these two receptors. Taken together, these results established that direct recruitment of BTG1 by nuclear receptors induces potentiation of their transcriptional activity, and consequently that BTG1 is to be considered as a coactivator molecule for particular nuclear receptors not including RXRa and PPARg.
Even more interesting is the observation that functional and physical BTG1 interactions are not restricted to nuclear receptors. As already established for CBP/ p300 (Kamei et al., 1996) , BTG1 both interacts with and stimulates the transcriptional activity of some nuclear receptors, myogenic factors and c-Jun. This pattern of interacting transcription factors satisfactorily explains the strong positive myogenic influence of BTG1. First, its expression is induced at a decisive step of the myogenic program characterized by the induction of myoblast withdrawal from the cell cycle and of terminal differentiation (Rodier et al., 1999) . Second, at this stage, BTG1 potentiates the influence of nuclear receptors (TRa1, RAR) involved in positive control of myoblast differentiation and of myogenic factors, by increasing their transcriptional activity. Such a role has already been proposed for CBP/p300 (Sartorelli et al., 1997) . Furthermore, its ability to interact with c-Jun is also probably involved in the myogenic activity of BTG1. Through its major interaction with c-Fos and Fra2 during proliferation, c-Jun represses myoblast withdrawal from the cell cycle; however, through a major interaction with ATF2, at the onset of differentiation and therefore concomitantly with BTG1 expression, c-Jun stimulates myogenin expression and myoblast differentiation . Therefore, as BTG1 is only expressed when c-Jun exerts a positive influence on myoblast differentiation, this mechanism could also be involved in its myogenic activity.
Whereas several coactivators mediate the influence of transcription factors through their own ability to acetylate histones and/or induce recruitment of other histone acetylases, BTG1 influence does not involve such a mechanism, as demonstrated by the lack of effect of trichostatin on the potentiation of TRa1 transcriptional activity. However, Lin et al. (1996) reported that BTG1 interacts with PRMT1, a protein methylating arginine residues occurring in histones. As a relationship between methylation of proteins and transcription factors activity has been described (Chen et al., 1999; Koh et al., 2001) , recruitment of PRMT1 by BTG1 could enhance their activity. However, we failed to observe any potentiation of TRa/BTG1 transcriptional activity by PRMT1 coexpression, in agreement with inability of BTG1 to interact with PRMT1 in the presence of TRa (data not shown). We obtained similar data indicating that PRMT1 does not affect CMD1/ BTG1 transcriptional activity, a result well supported by the observation that PRMT1 and CMD1 recognize a common BTG1 sequence (C box; Berthet et al., 2002; present data) , thus precluding an interaction including the three proteins. In addition, in these experiments, we unexpectedly found that PRMT1 is probably to be considered as a CMD1 coactivator. Although it remains to test a possible involvement of CAF-1, a component of the CCR4 transcriptional complex (Rouault et al., 1998) , one major observation is that BTG1 induces TRa1 transcriptional activity in the absence of RXR through a DR4 T3RE. As T3 is known to dissociate TR homodimers from this particular responsive element (Andersson et al., 1992) , this result indicates that BTG1 induces stabilization of the receptor's homodimeric binding to DNA in the presence of T3, in agreement with the possible formation of a stable transcriptional complex.
BTG1 interacting domains with TRa1 and CMD1 are both involved in stimulation of transcriptional activity and myoblast differentiation
We searched for the TRa1 and CMD1 sequences involved in the physical interactions with BTG1. We found that, in both proteins, sequences considered as BTG1: a myogenic coactivator M Busson et al inducing transcriptional activity, the AF2 domain for TRa1 (Wagner et al., 1995) or the 1-52 NH 2 -terminus for CMD1 (Weintraub et al., 1991) , are involved in the interaction with BTG1. Surprisingly, mutations or deletions of the BTG1 LxxLL sequences or of sequences encompassing them did not abrogate any interaction of this protein with TRa1 or CMD1. Instead, we found that the BTG1 A box, a well-conserved sequence in all members of the BTG family, with an unknown function prior to this study, interacts both with TRa1 and CMD1. In addition, whereas the C box, already shown to interact with PRMT1 (Berthet et al., 2002) , is specifically involved in the physical interaction with CMD1, the 129-171 BTG1 C-terminus interacts with TRa1. Therefore, recruitment of various transcription factors by BTG1 involves several domains of the protein.
In agreement with its coactivator activity, deletions of all BTG1 domains involved in the interactions with TRa1 or CMD1 abrogated its ability to stimulate the activity of transcription factors. Furthermore, as expected from our previous data, mutations of the LxxLL sequences did not alter the TRa1 and CMD1 coactivator functions (data not shown). All these data clearly established that the ability of BTG1 to stimulate TRa1 and CMD1 transcriptional activity needs physical interaction with these transcription factors.
Lastly, we also observed that deletion of all sequences inducing interactions with TRa1 and CMD1 completely abolished the positive influence of BTG1 on myoblast differentiation, thus demonstrating that impairment of the coactivator function of this protein fully abrogates its myogenic activity. This observation led us to conclude that stimulation of myoblast differentiation by BTG1 results from its ability to interact with and stimulate the activity of transcription factors positively regulating myogenic processes, in particular myogenic factors.
The present study is in line with a recent report indicating that BTG1 expression is induced by FoxO3A, a transcription factor involved in erythroid differentiation, and blocks the outgrowth of erythroid colonies (Bakker et al., 2004) . We demonstrate that BTG1 is a coactivator of hormone-dependent or constitutive transcription factors positively involved in the regulation of myoblast differentiation, such as TRa1, RAR and myogenic factors. In addition, we have established that alteration of this function severely impairs BTG1 myogenic influence. As we have previously shown that BTG1 expression is induced at the onset of myoblast differentiation, it appears that this coactivator could exert a key role in the proliferation/differentiation transition of myoblasts, by inducing stimulation of the expression of targets of nuclear receptors and myogenic factors. These data led us to propose that BTG1 is a nuclear coactivator of major importance for the regulation of myogenic processes, as supported by our observation indicating that expression of a BTG1 mRNA antisens significantly alters myoblast differentiation.
Materials and methods
Cell culture
Quail myoblasts of the QM7 cell line (Antin and Ordahl, 1991) were grown as described by Marchal et al. (1995) . Serum was T3-depleted according to Samuels et al. (1979) . In all, 10 nM T3 or 100 nM RA was added to the culture medium where indicated.
Plasmid and reporter genes
The DR4-tk-CAT plasmid was kindly provided by Pr P Chambon (LGME U184, Strasbourg, France). The gal4-tk-CAT reporter plasmid contains four response elements of the yeast transcription factor GAL4 upstream of the CAT coding sequence. The myogenin-CAT reporter plasmid has been described by Malik et al. (1995) . The À73col CAT collagenase plasmid has been described elsewhere (Angel et al., 1987) . The expression vector for chicken c-ErbAa1 (pRSV c-ErbAa1) has been described by Forman et al. (1989) . The pRSV Mgn and CMD1 expression vectors were provided by Dr C Deschene (INSERM, Nice, France). The expression vector pEMSV hMyf5 for human Myf5 was given by Dr D Montarras (Institut Pasteur, Paris, France).
The RSV (Rous sarcoma virus)-b-galactosidase expression vector has been described by Cassar-Malek et al. (1996) . The expression vectors for Gal4-c-ErbAa1 and Gal4-RAR (pSVGal4a1 and pCMXGal-L-hRARa) were provided by Dr F Flamant (ENS Lyon, France). The expression vectors for human BTG1 (pXT1-9) and for BTG1 mRNA antisens (pXTi) have been described by Rouault et al. (1992) . The expression vectors for quail c-Jun (pDP18 c-Jun) and chicken RXRg (pRSV RXRg) have been described by Vial et al. (2000) and Rowe et al. (1991) . The expression vector encoding NCoR (pCEP4 NCoR) has been described by Horlein et al. (1995) . The pGEM-T TRa1, pGEM-T TR(36-410) and pGEM-T TR(152-410) vectors were constructed by insertion of the corresponding 1.5, 1.1 and 1.0 kb EcoRI fragments of pSG5 plasmids described by Casas et al. (1999) into the EcoRI site of pGEM-T (Promega); they encode full-length and truncated versions of c-ErbAa1. The pCDM8 TRb1 plasmid was provided by Pr GH Williams (Imperial College, London).
pGEM-T TR(1-400), were generated by PCR from the pGEM-T TRa1 plasmid and inserted into the EcoRV site of pGEM-T plasmid. The pGEM-T BTG1, pGEM-T CMD1 and pGEM-T JUN plasmids were also generated by PCR from the pXT1-9, pRSV CMD1 and pDP18 c-Jun vectors respectively and cloned into the pGEM-T EcoRV site. The pGEM-T RARa was generated by PCR from the pRSV RARa vector provided by Dr J Samarut (ENS Lyon, France).
For in vitro protein synthesis, we fused full-length or different parts of human btg1 or CMD1 coding sequences belonging to pXT1-9 or pRSV CMD1 fused to the 3 0 end of the Escherichia coli GST gene. The cDNA sequences were generated by PCR using specific primers (Supplementary  material Table 1 ) and inserted into the SalI/NotI sites of the pGEX4T2 (Pharmacia) vector, in line with the gst coding sequence. Expression vectors for three BTG1 mutants, D BoxA, 1-117, 1-117 D BoxA, were inserted in-frame with the pSG5 expression vector.
Transient transfection and CAT assays
Transient transfections were performed using the calcium phosphate co-precipitation procedure (Wigler et al., 1978) as described by Cassar-Malek et al. (1996) . A 1 mg portion of BTG1: a myogenic coactivator M Busson et al pCMV b-galactosidase expression vector was cotransfected to provide an internal control of transfection efficiency. bGalactosidase activity was measured according to Nielsen et al. (1983) . CAT enzymatic activity was measured by following the kinetics of chloramphenicol acetylation as described by Cassar-Malek et al. (1996) . For each assay, the initial rate of enzymatic reaction was determined and results were expressed as a percentage of control values after bgalactosidase normalization.
In vitro transcription and translation
In vitro transcription and translation were carried out with TNT coupled reticulocyte lysate system (Promega) and trans-[ 35 S]methionine (ICN), according to the manufacturer's protocol. The proteins were processed for sodium docedyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE), and quantification of the relative intensities was carried out with a phosphoimager (Molecular Dynamics).
Co-immunoprecipitation
Immunoprecipitation of proteins was performed as described by Casas et al. (2000) using in vitro-synthesized 35 S-labelled BTG1, CMD1 and TRa1, or lysates from QM7 myoblasts overexpressing TRa1, CMD1, myogenin and/or a BTG1-flag protein. A 10 ml portion of each in vitro-synthesized protein was mixed with 1 ml of a17 antibody raised against TRa1, provided by Dr LJ De Groot (Chicago, Illinois) or raised against CMD1 or against myogenin, provided by Dr BM Paterson (University of Washington, Seattle). For cell culture experiments, myoblasts were collected 48 h after transfection of vectors encoding BTG1-flag, CMD1, myogenin and/or TRa1. Protein lysates (40 mg) were incubated with 1 ml of antibodies raised against TRa1, CMD1 or BTG1-flag (M2 monoclonal antibody, Sigma Laboratories). Immunoprecipitated TRa1 or CMD1 proteins were detected by Western blotting using appropriate antibodies. Revelation was performed using the ECF kit (Amersham Laboratories) when proteins were overexpressed, or the ECL kit (Amersham Laboratories) allowing to increase the revelation time in order to improve sensitivity when endogenous proteins were studied.
GST pull-down experiments
For GST pull-down experiments, similar amounts of GST fusion protein beads were incubated with 5 ml of in vitrotranslated proteins in binding buffer (20 mM Hepes pH 7.9, 50 mM KCl, 2.5 mM MgCl 2 , 10% glycerol, 1 mM DTT, 1 mM PMSF, 1 mg/ml aprotinin) overnight at 41C. After five washings in RIPA buffer (10 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.2% Nonidet P-40, 1 mM PMSF, 1 mg/ml aprotinin), the bound proteins were separated by SDS-PAGE, and the dried gel was exposed for autoradiography.
NCoR Northern blot
Total RNAs were extracted 48 h after transfection, using Trizol reagent (Invitrogen) as described by the supplier. Total RNAs (40 mg) were loaded in 1% agarose-formaldehyde gel. RNAs transferred onto nylon membrane (HybondN, Amersham) were hybridized with cDNA probes labelled with [ 32 P]adCTP using the megaprime DNA-labelling system (Amersham Pharmacia Biotech). A S26 ribosomal protein cDNA probe was used to provide an invariant control.
Assessment of myoblast differentiation
Cytoimmunofluorescence experiments were performed according to Marchal et al. (1995) using a monoclonal antibody raised against connectin (F146 9H8), kindly provided by Dr F Pons (INSERM Montpellier), and a fluorescein-conjugated antibody raised against mouse IgG. Observations were made with a standard Zeiss Axiophot immunofluorescence microscope.
In parallel, myoblast fusion was assessed by calculation of the fusion index, according to the following FI ¼ (NM Â 100)/ TN, with FI is the value of the fusion index, NM the number of nuclei included in myotubes in a microscopic field and TN the total number of nuclei in the same microscopic field. Countings were performed on 10 microscopic fields for each dish.
Expression of myosin heavy chain was assessed by Western blotting. Proteins (20 mg) were run on 10% SDS-PAGE minigels, transferred onto PVDF membrane and blotted with a monoclonal antibody raised against myosin heavy chain (F113 1F11), kindly provided by Dr F Pons (INSERM Montpellier), and detected by ECF (Amersham Pharmacia Biotech).
Statistical analysis
Statistical analyses were performed using the paired t-test (Snedecor, 1961) .
